m+Medelevator.RU
← Поиск публикаций
Frontiers in neurology · 2025

Association between C-reactive protein/albumin ratio and mortality in older Japanese patients with post-stroke dysphagia.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wang Ziying, Wang Lingling

Аннотация

INTRODUCTION: The C-reactive protein/albumin ratio (CAR) could serve as an novel obtainable application for prognosis. Few studies have assessed CAR and mortality in older Japanese patients with post-stroke dysphagia (PSD). We evaluated CAR as a composite prognostic factor and compared its predictive performance with C-reactive protein (CRP) and albumin.

METHODS: In this retrospective cohort study, 133 elderly Japanese patients with PSD (January 2014-January 2017) were analyzed. Cox proportional hazards models estimated associations of CAR, CRP, and albumin with mortality. Survival across CAR tertiles was compared by Kaplan-Meier curves. For 1-year mortality prediction we computed ROC curves and assessed incremental value using IDI and NRI.

RESULTS: Among 133 patients (78 women, 55 men; mean age 80.5 years), each one-unit increase in CAR was associated with a 42% higher hazard of death in unadjusted analysis (HR 1.42; 95% CI 1.18-1.71; p < 0.001) and remained significant after full adjustment (HR 1.49; 95% CI 1.16-1.92; p = 0.002). Higher CAR tertiles had worse survival (p < 0.0001). For 1-year mortality discrimination, CAR AUC = 0.702 (95% CI 0.606-0.798), albumin AUC = 0.710, CRP AUC = 0.685. Albumin improved prediction over CAR (IDI 0.108, p = 0.012; NRI 0.217, p = 0.044); CRP did not.

CONCLUSION: CAR was positively associated with mortality in older Japanese patients with PSD but had only modest discrimination for 1-year mortality. Albumin provided a small additional predictive benefit. Larger prospective studies are needed for validation.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты